At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 114 enrolled
Drug / intervention
N-acetylcysteine (NAC) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluating N-acetylcysteine as a Pharmacotherapy for Tobacco Use Disorder
In Brief
A Phase 2 clinical trial evaluating N-acetylcysteine (NAC) and Placebo for Nicotine Dependence and Smoking. Completed, enrolled 114 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the effects of administering N-Acetylcysteine (NAC) to assist in initial cessation and/or relapse prevention in adult cigarette smokers.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNicotine Dependence, Smoking
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedApr 2016
Enrollment StartAug 2016
Primary CompletionAug 2019
Study CompletionOct 2019
TodayJul 2026
First PostedApr 13, 2016
Enrollment StartAug 30, 2016
Primary CompletionAug 1, 2019
Study CompletionOct 10, 2019
TodayJul 2, 2026
Enrollment to primary: 2.9 yearsPosted 10.2 years ago
Interventions
N-acetylcysteine (NAC)drug
NAC or matched placebo will be given to study participants for 8 weeks.
Placeboother
Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.